Posted on: 26, August, 2025
Globalpharma, a wholly owned subsidiary of Dubai Investments and UAE’s leading pharmaceutical manufacturer, has signed a Memorandum of Understanding (MoU) with Angola’s Ministry of Health to establish a pharmaceutical manufacturing facility in DIP Angola.
The MoU reflects the strengthened bilateral relations highlighted during the recent UAE delegation visit to Angola, led by His Highness Sheikh Mohamed bin Zayed Al Nahyan, President of the United Arab Emirates, underscoring both nations’ commitment to advancing collaboration and sustainable growth across key sectors.
An estimated investment of approximately US$50 million has been allocated for this project, which will be rolled out in phases to strengthen local production of essential medicines and support Angola’s healthcare system. Under the agreement, Globalpharma will collaborate with Angola’s Ministry of Health to establish local manufacturing operations, creating hundreds of jobs, enhancing healthcare self-sufficiency, and reducing reliance on imported medical products — a significant milestone in reinforcing Angola’s healthcare ecosystem.
The MoU was signed by H.E. Khalid Bin Kalban, Vice Chairman and CEO of Dubai Investments, and Dr. Nídia da Silva Jorge Saiundo, representing the Ministry of Health, reinforcing the shared commitment to sustainable healthcare development in the country.
H.E. Khalid Bin Kalban, Vice Chairman and CEO of Dubai Investments, said: "This agreement marks more than a partnership — it represents a shared vision for the future of Angola’s healthcare landscape. Dubai Investments believes that sustainable growth comes from empowering nations to unlock their own potential. By aligning with Angola’s ambitions to become a regional hub for healthcare, Dubai Investments is investing not just in a project through this facility in DIP Angola, but in the foundations of long-term healthcare prosperity. This strategic collaboration reflects the Group’s commitment to building bridges between markets, accelerating Africa’s industrialization, and contributing to a more diversified and resilient global economy."
With over two decades of expertise, Globalpharma has established itself as a leading producer of high-quality generic and branded medicines across key therapeutic areas, including cardiovascular, anti-infective, gastrointestinal, and pain management. The company’s state-of-the-art manufacturing facilities are cGMP-certified and approved by health authorities across the GCC, Levant, Africa, and CIS regions.
Hon. Sílvia Paula Valentim Lutucuta, Minister of Health of Angola, commented: "This collaboration with DIP Angola and Globalpharma will strengthen Angola’s local production of essential medicines, reinforcing our healthcare system and ensuring greater access to high-quality medical products. By boosting domestic manufacturing, we are advancing toward self-sufficiency and improving the resilience of our healthcare sector."
The MoU formalizes the support and facilitation provided by the Ministry of Health for the successful implementation of DIP Angola’s projects. The Ministry will coordinate with relevant government bodies to expedite the issuance of licenses, permits, and regulatory approvals, as well as facilitate access to tax incentives, exemptions, and investment benefits in line with national laws and investment promotion regulations.
Dubai Investments has been steadily expanding its footprint in Angola over the past two years through the development of DIP Angola — the country’s first integrated economic zone. Modeled on Dubai Investments Park in the UAE, an integrated mixed-use development combining residential, commercial, and industrial components, DIP Angola is envisioned as a catalyst for Angola’s economic diversification, industrialization, and job creation.
This strategic collaboration underscores Angola’s commitment to advancing its healthcare capabilities by attracting experienced global partners. By combining Dubai Investments’ proven expertise through Globalpharma with Angola’s national priorities, the agreement lays the foundation for sustainable pharmaceutical production, stronger supply chains, and long-term economic resilience.
You can download our brochure for more information about the project Download